11/26
07:00 am
canf
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Medium
Report
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
11/24
07:00 am
canf
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
High
Report
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
11/20
07:00 am
canf
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
Medium
Report
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
11/18
02:57 pm
canf
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
Medium
Report
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
11/18
07:12 am
canf
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson [Yahoo! Finance]
High
Report
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson [Yahoo! Finance]
11/18
07:00 am
canf
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
High
Report
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
11/8
06:58 am
canf
Can-Fite BioPharma (NYSE:CANF) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Can-Fite BioPharma (NYSE:CANF) was upgraded by analysts at Zacks Research to a "hold" rating.
11/4
08:09 am
canf
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Low
Report
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
9/16
08:07 am
canf
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
Low
Report
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
9/15
07:19 am
canf
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson [Yahoo! Finance]
Low
Report
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson [Yahoo! Finance]
9/15
07:00 am
canf
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
High
Report
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson